ArticleCell host & microbe2021
Ultrapotent miniproteins targeting the SARS-CoV-2 receptor-binding domain protect against infection and disease.
Article in Cell host & microbe, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 67 citations in OpenAlex.
- Computational design of potent, broadly neutralizing anti-Nipah virus and Hendra virus miniproteins.bioRxiv : the preprint server for biology · 2026Article
- Scalable Production of aPharmaceutics · 2026Article
- De novo design of miniproteins targeting GPCRs.Nature · 2026Article
- Structure-Guided Design of Proteomimetics Targeting the SARS-CoV-2 S-RBD/hACE2 Interface.Journal of medicinal chemistry · 2026Article
- Targeting SARS-CoV-2 Structural and Accessory Proteins: Emerging Opportunities for Small-Molecule Coronavirus Antivirals.Pharmaceutics · 2026Review
- Computational design of an ultrapotent deltacoronavirus miniprotein inhibitor.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- AI-enabled protein design facilitates future plant research and crop breeding.Plant physiology · 2026Review
- Review
- Miniprotein inhibitors of thebioRxiv : the preprint server for biology · 2026Article
- De novo protein design: a transformative frontier in clinical protein applications.Journal of translational medicine · 2026Review
- Fusion of SARS-CoV-2 neutralizing LCB1 peptide with Bacillus amyloliquefaciens RNase improves antiviral efficacy.Scientific reports · 2025Article
- Article
- Designed miniproteins potently inhibit and protect against MERS-CoV.Cell reports · 2025Article
- Article
- Protein Nanoparticles for Targeted SARS-CoV-2 Trapping and Neutralization.Advanced healthcare materials · 2025Article
- Design of high-affinity binders to immune modulating receptors for cancer immunotherapy.Nature communications · 2025Article
- Structure-based computational design of antibody mimetics: challenges and perspectives.FEBS open bio · 2025Review
- Structure-guided engineering of a mutation-tolerant inhibitor peptide against variable SARS-CoV-2 spikes.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- ACVPICPred: Inhibitory activity prediction of anti-coronavirus peptides based on artificial neural network.Computational and structural biotechnology journal · 2024Article
- Targeting overexpressed antigens in glioblastoma via CAR T cells with computationally designed high-affinity protein binders.Nature biomedical engineering · 2024Article
Corrections and comments
- Update of
Authors and funding
18 authors at 4 institutions in 1 country.
Funding
Abstract
Despite the introduction of public health measures and spike protein-based vaccines to mitigate the COVID-19 pandemic, SARS-CoV-2 infections and deaths continue to have a global impact. Previously, we used a structural design approach to develop picomolar range miniproteins targeting the SARS-CoV-2 spike receptor-binding domain. Here, we investigated the capacity of modified versions of one lead miniprotein, LCB1, to protect against SARS-CoV-2-mediated lung disease in mice. Systemic administration of LCB1-Fc reduced viral burden, diminished immune cell infiltration and inflammation, and completely prevented lung disease and pathology. A single intranasal dose of LCB1v1.3 reduced SARS-CoV-2 infection in the lung when given as many as 5 days before or 2 days after virus inoculation. Importantly, LCB1v1.3 protected in vivo against a historical strain (WA1/2020), an emerging B.1.1.7 strain, and a strain encoding key E484K and N501Y spike protein substitutions. These data support development of LCB1v1.3 for prevention or treatment of SARS-CoV-2 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.